This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | MicrobiomeTrials
← Back to trials NCT06921850
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-04-07Est. Completion: 2026-12-21
Enrollment target: 43 participantsLocations Hs0006 50175, Phoenix, Arizona, United States Hs0006 50708, Roseville, California, United States Hs0006 50684, Sacramento, California, United States Hs0006 50707, Washington D.C., District of Columbia, United States Hs0006 50199, Miami, Florida, United States Hs0006 50712, Bowling Green, Kentucky, United States Hs0006 50178, Clarkston, Michigan, United States Hs0006 50710, Fort Gratiot, Michigan, United States Hs0006 50711, Troy, Michigan, United States Hs0006 50706, Chapel Hill, North Carolina, United States Hs0006 50202, Fairborn, Ohio, United States Hs0006 50201, Arlington, Texas, United States Hs0006 40326, Berlin, Germany Hs0006 40747, Mainz, Germany Hs0006 40625, Lodz, Poland Hs0006 40761, Warsaw, Poland Hs0006 40095, Wroclaw, Poland Hs0006 40845, Wroclaw, Poland Other microbiome trials you might be interested in Hidradenitis
This is a parallel, Phase 2b, 3-arm, double-blind, randomized, multicenter, multinational, placebo-controlled, dose-rang…
Multiple Locations Est. completion Jun 16, 2028
Hidradenitis Suppurativa Hyperhidrosis
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chro…
Worcester, United States Est. completion Apr 30, 2028